We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you accept our Privacy Policy and Terms of Service, revised from time to time, and you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why Retaining Cigna Stock is a Smart Move for Investors Now
Read MoreHide Full Article
The Cigna Group (CI - Free Report) continues to be aided by solid pharmacy revenues, a sound medical customer base, acquisitions and a robust financial position. A solid 2024 guidance acts as an additional tailwind for the company.
CI’s Zacks Rank & Price Performance
Cigna carries a Zacks Rank #3 (Hold) at present.
The stock has gained 17.1% in the past year compared with the industry’s 6.9% growth.
Image Source: Zacks Investment Research
Cigna’s Favorable Style Score
CI is well-poised for progress, as evidenced by its impressive VGM Score of B. Here V stands for Value, G for Growth and M for Momentum, and the score is a weighted combination of all three factors.
CI’s Robust Growth Prospects
The Zacks Consensus Estimate for CI’s 2024 earnings is pegged at $28.50 per share, indicating an improvement of 13.6% from the year-earlier reading. The estimate for revenues is $243.8 billion, implying a 24.8% increase from the prior-year actual.
The consensus mark for 2025 earnings is pegged at $31.59 per share, indicating 10.9% growth from the 2024 estimate. The estimate for revenues is $249.8 billion, which indicates a rise of 2.5% from the 2024 estimate.
Solid Surprise History of Cigna
Cigna’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 4.42%.
CI's Optimistic Outlook for 2024
Cigna anticipates adjusted revenues for 2024 to be a minimum of $235 billion, which indicates growth of at least 20.3% from the 2023 figure.
Adjusted earnings per share are predicted to be a minimum of $28.40, which implies minimum growth of 13.2% from the 2023 figure.
Cigna’s Growth Drivers
Cigna’s performance is underpinned by two robust growth platforms- Evernorth and Cigna Healthcare- which keep management optimistic about achieving average annual adjusted earnings per share growth within the band of 10-14% in the long term.
The Evernorth platform fuels its growth through a comprehensive range of specialty pharmacy services, thereby significantly boosting pharmacy revenues for the parent company. In the first nine months of 2024, pharmacy revenues surged 35% year over year.
Simultaneously, the Cigna Healthcare unit benefits from an extensive customer base within its U.S. Healthcare operations. The unit is projected to deliver long-term average annual adjusted earnings per share growth between 7% and 10%. An increasing customer base translates to higher premium income, the largest revenue source for health insurers. Additionally, an aging U.S. population is expected to sustain the strong demand for its Medicare plans.
Beyond premium growth, Cigna Healthcare gains from continuous product innovation, along with new collaborations and extended contracts with leading healthcare systems.
Cigna also employs strategic acquisitions to broaden its capabilities, penetrate new regions and bolster its position in existing markets. To concentrate on high-growth areas, the company has divested its non-health-related units.
Cigna’s sound cash reserves and cash generation capabilities provide the flexibility to invest in business expansion while maintaining shareholder returns through share repurchases and dividend payments. Over the next five years, management projects operating cash flows of approximately $60 billion. The company approved a 14% increase in its quarterly dividend this February. Its dividend yield of 1.7% remains higher than the industry average of 1.4%.
Tenet Healthcare’s earnings surpassed estimates in each of the last four quarters, the average surprise being 59.92%. The Zacks Consensus Estimate for THC’s 2024 earnings indicates a 63% rise while the same for revenues implies an improvement of 1.1% from the respective prior-year tallies. The consensus mark for THC’s earnings has moved 6.8% north in the past 30 days.
The bottom line of ANI Pharmaceuticals outpaced estimates in each of the trailing four quarters, the average surprise being 20.27%. The Zacks Consensus Estimate for ANIP’s 2024 earnings indicates a 6.6% rise while the same for revenues implies an improvement of 23% from the respective prior-year tallies. The consensus mark for ANIP’s earnings has moved 6.1% north in the past 30 days.
Intuitive Surgical’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 10.96%. The Zacks Consensus Estimate for ISRG’s 2024 earnings indicates a 20.5% rise while the same for revenues implies an improvement of 14.1% from the respective prior-year tallies. The consensus mark for ISRG’s earnings has moved up 3.1% in the past 60 days.
Shares of Tenet Healthcare, ANI Pharmaceuticals and Intuitive Surgical have gained 114.7%, 15.1% and 71.4%, respectively, in the past year.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.
Image: Bigstock
Here's Why Retaining Cigna Stock is a Smart Move for Investors Now
The Cigna Group (CI - Free Report) continues to be aided by solid pharmacy revenues, a sound medical customer base, acquisitions and a robust financial position. A solid 2024 guidance acts as an additional tailwind for the company.
CI’s Zacks Rank & Price Performance
Cigna carries a Zacks Rank #3 (Hold) at present.
The stock has gained 17.1% in the past year compared with the industry’s 6.9% growth.
Image Source: Zacks Investment Research
Cigna’s Favorable Style Score
CI is well-poised for progress, as evidenced by its impressive VGM Score of B. Here V stands for Value, G for Growth and M for Momentum, and the score is a weighted combination of all three factors.
CI’s Robust Growth Prospects
The Zacks Consensus Estimate for CI’s 2024 earnings is pegged at $28.50 per share, indicating an improvement of 13.6% from the year-earlier reading. The estimate for revenues is $243.8 billion, implying a 24.8% increase from the prior-year actual.
The consensus mark for 2025 earnings is pegged at $31.59 per share, indicating 10.9% growth from the 2024 estimate. The estimate for revenues is $249.8 billion, which indicates a rise of 2.5% from the 2024 estimate.
Solid Surprise History of Cigna
Cigna’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 4.42%.
CI's Optimistic Outlook for 2024
Cigna anticipates adjusted revenues for 2024 to be a minimum of $235 billion, which indicates growth of at least 20.3% from the 2023 figure.
Adjusted earnings per share are predicted to be a minimum of $28.40, which implies minimum growth of 13.2% from the 2023 figure.
Cigna’s Growth Drivers
Cigna’s performance is underpinned by two robust growth platforms- Evernorth and Cigna Healthcare- which keep management optimistic about achieving average annual adjusted earnings per share growth within the band of 10-14% in the long term.
The Evernorth platform fuels its growth through a comprehensive range of specialty pharmacy services, thereby significantly boosting pharmacy revenues for the parent company. In the first nine months of 2024, pharmacy revenues surged 35% year over year.
Simultaneously, the Cigna Healthcare unit benefits from an extensive customer base within its U.S. Healthcare operations. The unit is projected to deliver long-term average annual adjusted earnings per share growth between 7% and 10%. An increasing customer base translates to higher premium income, the largest revenue source for health insurers. Additionally, an aging U.S. population is expected to sustain the strong demand for its Medicare plans.
Beyond premium growth, Cigna Healthcare gains from continuous product innovation, along with new collaborations and extended contracts with leading healthcare systems.
Cigna also employs strategic acquisitions to broaden its capabilities, penetrate new regions and bolster its position in existing markets. To concentrate on high-growth areas, the company has divested its non-health-related units.
Cigna’s sound cash reserves and cash generation capabilities provide the flexibility to invest in business expansion while maintaining shareholder returns through share repurchases and dividend payments. Over the next five years, management projects operating cash flows of approximately $60 billion. The company approved a 14% increase in its quarterly dividend this February. Its dividend yield of 1.7% remains higher than the industry average of 1.4%.
Stocks to Consider
Some better-ranked stocks in the Medical space are Tenet Healthcare Corporation (THC - Free Report) , ANI Pharmaceuticals, Inc. (ANIP - Free Report) and Intuitive Surgical, Inc. (ISRG - Free Report) . Tenet Healthcare sports a Zacks Rank #1 (Strong Buy), and ANI Pharmaceuticals and Intuitive Surgical carry a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Tenet Healthcare’s earnings surpassed estimates in each of the last four quarters, the average surprise being 59.92%. The Zacks Consensus Estimate for THC’s 2024 earnings indicates a 63% rise while the same for revenues implies an improvement of 1.1% from the respective prior-year tallies. The consensus mark for THC’s earnings has moved 6.8% north in the past 30 days.
The bottom line of ANI Pharmaceuticals outpaced estimates in each of the trailing four quarters, the average surprise being 20.27%. The Zacks Consensus Estimate for ANIP’s 2024 earnings indicates a 6.6% rise while the same for revenues implies an improvement of 23% from the respective prior-year tallies. The consensus mark for ANIP’s earnings has moved 6.1% north in the past 30 days.
Intuitive Surgical’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 10.96%. The Zacks Consensus Estimate for ISRG’s 2024 earnings indicates a 20.5% rise while the same for revenues implies an improvement of 14.1% from the respective prior-year tallies. The consensus mark for ISRG’s earnings has moved up 3.1% in the past 60 days.
Shares of Tenet Healthcare, ANI Pharmaceuticals and Intuitive Surgical have gained 114.7%, 15.1% and 71.4%, respectively, in the past year.